RxSight, Inc. develops and sells ophthalmic medical technology for customized vision after cataract surgery. Its RxSight Light Adjustable Lens system includes Light Adjustable Lens products, the Light Delivery Device and related accessories, enabling post-operative adjustment of an intraocular lens based on patient visual feedback.
RxSight news commonly covers financial results, sales guidance, Light Adjustable Lens unit demand, Light Delivery Device placements and installed-base growth. Company updates also address clinical evidence presented in cataract and refractive surgery forums, regulatory approvals in international markets, healthcare conference participation and executive finance leadership changes.
RxSight (NASDAQ: RXST) reported third-quarter 2026 revenue of $24.6 million, down from the prior-year period as losses widened. Revenue fell 19% year over year, primarily reflecting competitive pressures, and included 23,128 Light Adjustable Lens units. Gross margin declined to 73.6% from 79.9%, reflecting higher inventory reserves and costs, partly offset by product mix. Net loss widened to $16.224 million, or $0.39 per share, from $9.816 million, or $0.24 per share.
Cash, cash equivalents and short-term investments totaled $254.7 million at September 30, including $60 million received during the quarter from the Alcon collaboration. Collaboration revenue was $40,000, and the agreement's initial 120-day period was complete. RxSight completed organizational restructuring intended to reduce core operating expenses and is advancing a commercial transformation that includes nearly doubling its sales force.
RxSight (RXST) granted inducement stock options covering 236,456 common shares to two new non-executive officer employees as they began employment.
The options were granted on October 23, 2026, with an exercise price of $5.02 per share, equal to the closing share price that day. RxSight also agreed to grant the same employees restricted stock units (RSUs), awards covering 637,449 common shares, anticipated on or about November 3, 2026. The awards fall under the 2026 Inducement Equity Incentive Plan and Nasdaq Listing Rule 5635(c)(4).
RxSight (RXST) will report its third-quarter 2026 financial results after the market closes on November 3, 2026.
Management will discuss the results on a conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern. A live, listen-only webcast will be available on the company’s investor relations website, with an archived recording available shortly after the call ends.
RxSight (RXST) appointed Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy.
The appointments accompany a broader commercial transformation that includes expanding and realigning the field organization. RxSight said the changes are intended to deepen customer engagement, help practices integrate its Light Adjustable Lens technology into their workflows and address barriers to broader use. Conway brings more than 20 years of experience across eye care, pharmaceuticals and medical aesthetics; Shields brings over 30 years of ophthalmology leadership experience.
RxSight (NASDAQ: RXST) announced that its management will participate in the Wells Fargo Healthcare Conference in Boston, Massachusetts, on Wednesday, September 9, 2026, at 9:30 a.m. ET. A live and archived webcast of the presentation will be accessible via the company’s investor relations website.
RxSight (NASDAQ: RXST) reported Q2 2026 revenue of $33.7 million, essentially flat year over year, including $6.5 million from its new strategic collaboration with Alcon. Product sales were $27.2 million, down 19%, with 24,917 Light Adjustable Lens units and 12 Light Delivery Devices sold.
Excluding collaboration revenue, gross margin was 71.2% versus 74.9% a year ago; including it, gross margin was 76.7%. Operating expenses were $39.7 million. Net loss was $12.1 million (basic and diluted $(0.29) per share). Adjusted net loss was $4.6 million, or $(0.11) per share. Cash, cash equivalents and short-term investments totaled $208.8 million on June 30, 2026.
RxSight appointed Aziz Mottiwala as President and CEO, entered a collaboration with Alcon that includes up to $200 million in upfront and milestone payments plus future royalties, and announced development of a next-generation Light Adjustable Technology platform. In connection with the leadership transition, the company withdrew its 2026 guidance and plans to resume formal guidance in early 2027.
RxSight (NASDAQ: RXST) reported that on July 24, 2026 it granted inducement equity awards to new President and CEO Aziz Mottiwala in connection with his employment. The awards include stock options for 571,286 shares at an exercise price of $5.19 and RSUs covering 2,312,138 shares.
The options vest 25% on the one-year anniversary of July 24, 2026, with the remainder vesting in equal monthly installments over the following three years. The RSUs vest 20% on each of the first two anniversaries and 60% on the third anniversary. The grants were made under the 2026 Inducement Equity Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
RxSight (NASDAQ: RXST) announced a planned leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue with the company as Chief Medical Officer.
According to RxSight, Mottiwala brings extensive commercial eye-care experience, including prior Chief Commercial Officer roles at Tarsus Pharmaceuticals and Opiant Pharmaceuticals and senior leadership positions at Allergan. Dr. Kurtz, recognized for his role in establishing adjustability in the ophthalmic marketplace, will focus on advancing RxSight’s technology, clinical value, and expansion of adjustability into broader market segments as CMO. As part of the transition, Dr. Kurtz will resign from the Board of Directors, and Mottiwala will be appointed to the Board. RxSight stated it is not updating its previously communicated financial guidance in connection with this announcement.
RxSight (NASDAQ: RXST) expects preliminary Q2 2026 revenue of $32–$34 million, including $5–$7 million from its Alcon collaboration. Product sales are about $27 million, with 24,917 LAL units and 11 LDD units sold, and cash of $209 million on June 30, 2026.
For 2026, revenue guidance is $140–$160 million, with sales of $110–$120 million (reduced from $120–$135 million) and collaboration revenue of $30–$40 million. Gross margin is guided to 73–75%, above prior 70–72%, and operating expenses are expected at the high end of $150–$160 million. The company also highlighted a next-generation Light Adjustable Technology platform, including new LAL, LAL+ and LAL Toric lenses, alongside its strategic collaboration with Alcon on light-adjustable presbyopia-correcting intraocular lenses.
Alcon (NYSE:ALC) and RxSight (NASDAQ:RXST) entered a non-exclusive license and development agreement to create adjustable presbyopia-correcting intraocular lenses (PCIOLs).
RxSight receives a $60 million upfront payment, up to $140 million in development and regulatory milestones, and royalties, while Alcon leads global commercialization and RxSight handles development and manufacturing.